DK406686D0 - Carboxylsyrederivater - Google Patents

Carboxylsyrederivater

Info

Publication number
DK406686D0
DK406686D0 DK406686A DK406686A DK406686D0 DK 406686 D0 DK406686 D0 DK 406686D0 DK 406686 A DK406686 A DK 406686A DK 406686 A DK406686 A DK 406686A DK 406686 D0 DK406686 D0 DK 406686D0
Authority
DK
Denmark
Prior art keywords
carboxylic acid
acid derivatives
derivatives
carboxylic
acid
Prior art date
Application number
DK406686A
Other languages
Danish (da)
English (en)
Inventor
Hans Bundgaard
Niels Moerk Nielsen
Original Assignee
Hans Bundgaard
Niels Moerk Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hans Bundgaard, Niels Moerk Nielsen filed Critical Hans Bundgaard
Priority to DK406686A priority Critical patent/DK406686D0/da
Publication of DK406686D0 publication Critical patent/DK406686D0/da
Priority to PCT/DK1987/000104 priority patent/WO1988001615A1/en
Priority to US07/188,407 priority patent/US5073641A/en
Priority to AU79602/87A priority patent/AU7960287A/en
Priority to JP62505328A priority patent/JPH01501310A/ja
Priority to AT87905946T priority patent/ATE75725T1/de
Priority to EP87905946A priority patent/EP0278977B1/de
Priority to DE8787905946T priority patent/DE3778873D1/de
Priority to CA000545423A priority patent/CA1325422C/en
Priority to DK227088A priority patent/DK167007B1/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/281-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK406686A 1986-08-26 1986-08-26 Carboxylsyrederivater DK406686D0 (da)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK406686A DK406686D0 (da) 1986-08-26 1986-08-26 Carboxylsyrederivater
PCT/DK1987/000104 WO1988001615A1 (en) 1986-08-26 1987-08-25 Prodrug derivatives of carboxylic acid drugs
US07/188,407 US5073641A (en) 1986-08-26 1987-08-25 Prodrug derivatives of carboxylic acid drugs
AU79602/87A AU7960287A (en) 1986-08-26 1987-08-25 Prodrug derivatives of carboxylic acid drugs
JP62505328A JPH01501310A (ja) 1986-08-26 1987-08-25 カルボン酸薬物のプロドラッグ誘導体
AT87905946T ATE75725T1 (de) 1986-08-26 1987-08-25 Derivate von vorstufen von carboxylsaeuremedikamenten.
EP87905946A EP0278977B1 (de) 1986-08-26 1987-08-25 Derivate von vorstufen von carboxylsäure-medikamenten
DE8787905946T DE3778873D1 (de) 1986-08-26 1987-08-25 Derivate von vorstufen von carboxylsaeure-medikamenten.
CA000545423A CA1325422C (en) 1986-08-26 1987-08-26 Prodrug derivatives of carboxylic acid drugs
DK227088A DK167007B1 (da) 1986-08-26 1988-04-26 Prodrugderivater af carboxylsyre-laegemidler, en fremgangsmaade til fremstilling heraf samt et praeparat indeholdende disse derivater

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK406686A DK406686D0 (da) 1986-08-26 1986-08-26 Carboxylsyrederivater

Publications (1)

Publication Number Publication Date
DK406686D0 true DK406686D0 (da) 1986-08-26

Family

ID=8129825

Family Applications (1)

Application Number Title Priority Date Filing Date
DK406686A DK406686D0 (da) 1986-08-26 1986-08-26 Carboxylsyrederivater

Country Status (7)

Country Link
US (1) US5073641A (de)
EP (1) EP0278977B1 (de)
JP (1) JPH01501310A (de)
AU (1) AU7960287A (de)
CA (1) CA1325422C (de)
DK (1) DK406686D0 (de)
WO (1) WO1988001615A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380705A (zh) * 2022-01-11 2022-04-22 四川大学 一种利用模拟酪氨酸羟化酶制备的纳米酶仿生合成左旋多巴的方法

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
JPS6425782A (en) * 1987-03-27 1989-01-27 Yoshitomi Pharmaceutical Benzopyranopyridineacetic acid ester compound
DK24089D0 (da) * 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5637616A (en) * 1993-06-18 1997-06-10 Arcturus Pharmaceutical Corporation Method for treating diseases mediated by proteases
US5458883A (en) 1994-01-12 1995-10-17 Duke University Method of treating disorders of the eye
IT1274175B (it) * 1994-11-22 1997-07-15 Lab Alchemia Srl Procedimento per la preparazione di una combinazione chimica farmacologicamente attiva
DE19529604A1 (de) * 1995-08-11 1997-02-13 Bayer Ag Endoparasitizide Mittel auf Basis von Didepsipeptiden, neue Didepsipeptide und ein Verfahren zu ihrer Herstellung
US6071934A (en) * 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
IT1290447B1 (it) * 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
US6501188B1 (en) * 1997-07-03 2002-12-31 Micron Technology, Inc. Method for improving a stepper signal in a planarized surface over alignment topography
US20020128301A1 (en) * 1998-02-13 2002-09-12 Medivir AB Non-nucleoside reverse transcriptase inhibitors
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US8722668B2 (en) 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
WO2002078681A2 (en) 2001-04-02 2002-10-10 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
CA2477004C (en) * 2002-02-22 2011-05-10 Thomas Piccariello Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
EP1481078A4 (de) * 2002-02-22 2006-08-16 New River Pharmaceuticals Inc Verwendung einer peptid-arzneistoff-konjugation zur reduzierung der variabilität von arzneistoff-serumspiegeln zwischen patienten
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
JP2005529892A (ja) * 2002-04-26 2005-10-06 イーライ・リリー・アンド・カンパニー 鎮痛剤としてのデカヒドロイソキノリン−3−カルボン酸のエステルプロドラッグ
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
DE60332163D1 (de) * 2002-12-27 2010-05-27 Daiichi Sankyo Healthcare Co Zusammensetzung zur hautaufhellung
US20030187072A1 (en) * 2003-02-14 2003-10-02 Kapin Michael A. Method of treating angiogenesis-related disorders
AU2004251647B2 (en) * 2003-05-29 2010-01-14 Takeda Pharmaceutical Company Limited Abuse resistant amphetamine compounds
BRPI0414876A (pt) * 2003-09-30 2006-11-21 New River Pharmaceuticals Inc compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
US8157788B2 (en) * 2003-11-06 2012-04-17 Paolo L. Manfredi Multi-site drug delivery platform
JP4781352B2 (ja) * 2004-06-04 2011-09-28 ゼノポート,インコーポレーテッド レボドパプロドラッグおよびその組成物ならびにその使用
US7323585B2 (en) 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20060135609A1 (en) * 2004-10-21 2006-06-22 Duke University Ophthamological drugs
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20070053984A1 (en) * 2005-03-03 2007-03-08 Monique Spann-Wade Topical gels compositions
JP2009511629A (ja) * 2005-10-17 2009-03-19 ニューロセラピューティクス ファーマ, インコーポレイテッド 中枢神経系疾患の調節に有用な利尿薬様化合物類似体
ES2391575T3 (es) 2005-12-05 2012-11-27 Xenoport, Inc. Mesilato de profármaco de Levodopa, sus composiciones y sus usos
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
TW200844079A (en) * 2006-12-19 2008-11-16 Versitech Ltd Synthetic ion channels
WO2008079387A1 (en) 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
JP2010524959A (ja) 2007-04-17 2010-07-22 コドマン・アンド・シャートレフ・インコーポレイテッド アルツハイマー病を処置するためのヘリウムガスボーラス中のクルクミンの鼻腔投与
US8383865B2 (en) 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
US20090069419A1 (en) * 2007-09-07 2009-03-12 Bernd Jandeleit Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033079A1 (en) * 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
US7745670B2 (en) * 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス, インコーポレイテッド 水溶性アセトアミノフェン類似体
EP2291084A4 (de) * 2008-05-20 2012-04-25 Neurogesx Inc Carbonat-prodrugs und verfahren zu ihrer verwendung
US7985776B2 (en) * 2008-06-27 2011-07-26 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
PL2334378T3 (pl) 2008-08-19 2014-09-30 Xenoport Inc Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania
JP2012505885A (ja) * 2008-10-20 2012-03-08 ゼノポート,インコーポレーテッド レボドパエステルプロドラッグを合成する方法
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US7723515B1 (en) 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
AU2010315892B2 (en) 2009-11-09 2014-09-18 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
EP2569023B1 (de) * 2010-05-10 2015-10-21 SurModics, Inc. Systeme und verfahren zur abgabe von glycerolesterwirkstoff
US9861727B2 (en) 2011-05-20 2018-01-09 Surmodics, Inc. Delivery of hydrophobic active agent particles
JP2015526477A (ja) 2012-08-22 2015-09-10 ゼノポート,インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US11246963B2 (en) 2012-11-05 2022-02-15 Surmodics, Inc. Compositions and methods for delivery of hydrophobic active agents
US9555119B2 (en) 2012-11-05 2017-01-31 Surmodics, Inc. Composition and method for delivery of hydrophobic active agents
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2017180723A1 (en) 2016-04-12 2017-10-19 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
EP3592730B1 (de) 2017-03-09 2021-08-04 Truly Translational Sweden AB Prodrugs von sulfasalazin, pharmazeutische zusammensetzungen davon und deren verwendung in der behandlung von autoimmunkrankheiten
JP7197880B2 (ja) * 2017-10-19 2022-12-28 学校法人 名城大学 エステル化剤及びその利用
CN113677660A (zh) * 2018-12-29 2021-11-19 张婧 乙酰水杨酸衍生物及其应用
GB202111866D0 (en) 2021-08-18 2021-09-29 Ucl Business Plc Prodrugs for use in the treatment of tissue damage
CN117843589A (zh) * 2022-10-09 2024-04-09 天津谷堆生物医药科技有限公司 取代3-氟苯丙酸酯类化合物及其制备方法、药物组合及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE734487A (de) * 1968-07-11 1969-12-12
US4235887A (en) * 1977-04-13 1980-11-25 The Upjohn Company Process for therapeutic treatment
US4206220A (en) * 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents
US4363817A (en) * 1981-08-27 1982-12-14 Miles Laboratories, Inc. Enol acylate analogs of E1 and E2 prostaglandins
FR2514355A1 (fr) * 1981-10-14 1983-04-15 Fabre Sa Pierre Derives de biphenyl alcoyl carboxylates, leur procede de preparation et leur utilisation comme medicaments
IL69593A (en) * 1982-09-17 1988-09-30 Bundegaard Hans Pilocarpine prodrugs,their preparation and pharmaceutical compositions containing them
US4588525A (en) * 1984-02-27 1986-05-13 Molecular Biosystems, Inc. Prodrug compounds for dermal application
AU594645B2 (en) * 1984-06-08 1990-03-15 Ciba-Geigy Ag N-substituted butyramide derivatives
DE3517535A1 (de) * 1985-05-15 1986-11-20 Bayer Ag, 5090 Leverkusen 1-aryl-4-chinolon-3-carbonsaeuren
DE3542002A1 (de) * 1985-11-28 1987-06-04 Bayer Ag 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
EP0237051B1 (de) * 1986-03-14 1991-05-02 Fujisawa Pharmaceutical Co., Ltd. Prodrugverbindungen, Verfahren zu deren Herstellung und diese enthaltende Zubereitungen mit verzögerter Freisetzung
US4678806A (en) * 1986-09-02 1987-07-07 Merck & Co., Inc. Prodrugs of antihypercholesterolemic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380705A (zh) * 2022-01-11 2022-04-22 四川大学 一种利用模拟酪氨酸羟化酶制备的纳米酶仿生合成左旋多巴的方法

Also Published As

Publication number Publication date
EP0278977A1 (de) 1988-08-24
US5073641A (en) 1991-12-17
AU7960287A (en) 1988-03-24
JPH01501310A (ja) 1989-05-11
WO1988001615A1 (en) 1988-03-10
CA1325422C (en) 1993-12-21
EP0278977B1 (de) 1992-05-06

Similar Documents

Publication Publication Date Title
DK406686D0 (da) Carboxylsyrederivater
DK686487A (da) 1h-imidazol-5-carboxylsyrederivater
DK259386D0 (da) Thiazolidincarboxylsyrederivater
IT1205123B (it) Acidi bifenil-idrossamici
DE3872937D1 (de) Benzoylaminophenoxybuttersaeure-derivate.
DE68913137D1 (de) Carbonsäure-Derivate.
DK101287A (da) 1h-imidazol-5-carboxylsyrederivater
DK655487D0 (da) Furanuronsyrederivater
DK340886A (da) Substituerede benzoesyrederivater
DK549888A (da) Catechol-carboxylsyrederivater
GB8630759D0 (en) Carboxylic acid derivatives
DK340485D0 (da) Phenylnonatetraensyrederivater
DK670589D0 (da) Carboxylsyrederivater
DK426288D0 (da) Naphthalenpropionsyrederivater
DK718488A (da) Hydrogenerede 1-benzooxacycloalkylpyridincarboxylsyreforbindelser
DE3768557D1 (de) Trans-hexahydroterephthalsaeureesterderivate.
DK317985D0 (da) Aminoeburnancarboxylsyrederivater
DK428087D0 (da) Dihydropyridin-5-phosphonsyre-cyclopropylenester
DK318085A (da) Nitroapovincaminsyrederivater
DK527486A (da) Substituerede 1-amino-cyclopropancarboxylsyrederivater
DK538689D0 (da) Penicillansyrederivater
DK234485A (da) Substituerede phenoxyphenylpropionsyrederivater
DK304389A (da) Carboxylsyrederivater
IE861892L (en) Carboxylic acid derivatives
GB8607839D0 (en) Carboxylic acid derivatives

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment